![Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience - Lung Cancer Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9236286b-a16f-4e90-979a-4bbbb65d82cb/gr1_lrg.jpg)
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience - Lung Cancer
![Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer - ScienceDirect Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S016836591830364X-fx1.jpg)
Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer - ScienceDirect
![Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study - Journal of Thoracic Oncology Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040424174/2053919182/gr1.jpg)
Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study - Journal of Thoracic Oncology
![Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer - Journal of Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer - Journal of](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040329461/2053819815/gr1.jpg)
Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer - Journal of
البورد العراقي للصيدلة السريرية - Alimta® (pemetrexed) 💎 Note: Start vitamin supplements 1 week before initial pemetrexed dose: Folic acid 400 to 1,000 mcg orally once daily (begin 7 days prior to
![Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) - Annals of Oncology Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/49792743-57fe-49fc-962f-f98b5e025821/gr1_lrg.jpg)
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) - Annals of Oncology
![A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/bad6523d-6b9f-43b0-8662-ea2c7991f945/gr1_lrg.jpg)
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in
![Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non–Small-cell Lung Cancer - Clinical Lung Cancer Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non–Small-cell Lung Cancer - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/46553461-d9e6-49e7-9857-291ddb069cb0/gr1_lrg.jpg)
Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non–Small-cell Lung Cancer - Clinical Lung Cancer
![Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling | Drug Metabolism & Disposition Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling | Drug Metabolism & Disposition](https://dmd.aspetjournals.org/content/dmd/43/3/325/F4.large.jpg)